Japanese firm Eisai Co., Ltd. as part of its strategic investment to realize its medium-term management plan, EWAY ...
Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-hou...
Eisai Co., Ltd. has announced that Eisai Korea Inc., (Eisai's subsidiary in South Korea) has launched the Parkinson's di...
Standigm Inc, an artificial intelligence (AI)-based drug discovery company and SK Chemicals Co, Ltd, a life science and ...
Chugai Pharmaceutical Co., Ltd. announced that Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obta...
AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chro...
Gilead Sciences K.K. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Luc Hermans) and Eisai Co.,...
Singapore's Health Sciences Authority (HSA) recently approved an immunotherapy regimen (Tecentriq + Avastin) t...
A NEW therapy to treat advanced gastrointestinal stromal tumours (GIST) will be available to patients in Australia,...
TaiGen Biotechnology Company, Limited (TaiGen) in Taiwan has announced that U.S. Food and Drug Administration (FDA) has ...
Microcrystal electron diffraction (MicroED) is a new crystal structure determination technique for small molecules. It o...
Japanese firm FUJIFILM Toyama Chemical Co., Ltd. has announced that the company filed an Application for Partial Changes...
The Indian state, Maharashtra has become the first to fix the price of remdesivir at INR2,360 (US$32.17), which is 16% m...
Eisai Co., Ltd. on 16 Oct 2020 announced that the supplementary new drug applications for its in-house discovered and de...
